Skip to main content

Table 1 Patient characteristics

From: A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy

 

1

2

3

4

5

6

7

8

9

10

Age (year)

69

74

57

45

74

63

76

68

73

71

Gender (M/F)

M

M

F

M

M

F

F

M

F

F

Primary

Lung

Pancreas

Ileum

Ileum

Unknown

MTC*

Ileum

Pancreas

Unknown

Ileum

Grade

2

1

1

2

1

NA

2

1

1

1

MIB-1

3-20%

2%

1%

1%

1%

NA

5%

2%

1%

2%

Ki-67

NA

2-5%

3%

2%

0

NA

5%

0%

0%

1%

Resection primary

Y

N

Y

Y

N

Y

N

N

Y

Y

Liver embolization

N

Y

Y

Y

N

N

N

N

N

N

SSA therapy

Y

Y

Y

Y

Y

N

N

Y

Y

Y

Chemo/targeted therapy

N

N

N

N

N

N

N

Y

N

N

Metastatic sides

Liver, LN, bone, other

Liver, LN, bone

Liver, LN, bone

Liver, other

Liver, LN, bone, other

LN

Liver, LN, bone, other

Liver, LN, other

Liver, LN, bone, other

Liver, LN, bone, other

Tumour lesions included

None

Liver: 3

Other: 1

Liver: 2

Other: 1

Liver: 2

Liver: 2

Other: 2

Other: 1

Liver: 4

Other: 1

Liver: 5

Other: 1

Liver: 1

Other: 1

Liver: 2

Administered activity (MBq)

7131

7253

7176

7271

7188

7212

7613

7476

7338

7373

  1. *Medullar thyroid carcinoma
  2. LN lymph nodes; NA not available; SSA therapy somatostatin analogue use during PRRT treatment
  3. *†Age at start PRRT